You are still incorrect. A preexisting contract that was previously disclosed does not have to be disclosed again. If either party terminated it it would be a material event that also would need to be reported, particularly if it is before they have an alternative provider in the US.
The existing contract had two arms to it: 1) production for the trials, which is done; and 2) an optional it’s claims that only kicks in upon approval, when they have terms to negotiate the costs of production for commercial sales.
They can in fact negotiate a confidential letter subject to the condition that they are approved, with terms listed some still to be finalized and provide that to a regulator. That is clearly sufficient to meet the obligations that we were discussing, which were not about current production but proof of capacity to scale upon approval.
So quit it with the overly dramatic, misdirection.